BioSpace News Archive

FDA

FDA Approves Bausch + Lomb, Novaliq Dry Eye Disease Drug

The regulator’s approval makes Miebo the first DED treatment that directly addresses tear evaporation. The drug is expected to hit U.S. markets in the second half of 2023.

May 19, 2023
·
2 min read
·
Tristan Manalac
FDA

AbbVie Adds Crohn’s Disease to Rinvoq’s Growing List of Indications

Crohn’s disease is Rinvoq’s seventh approved indication and could potentially help AbbVie weather declining sales for its blockbuster biologic Humira.

May 19, 2023
·
2 min read
·
Tristan Manalac
Policy

FDA Action Alert: Blueprint, Indivior and Lexicon

Blueprint Medicines, Indivior PLC and Lexicon Pharmaceuticals are all awaiting FDA decisions this week.

May 19, 2023
·
4 min read
·
Tristan Manalac
CorFlow Announces Positive Data from the MOCA I First in Human Study Presented at EuroPCR 2023

CorFlow Therapeutics AG has announced the interim positive results of its MOCA I study at EuroPCR in Paris, France.

May 19, 2023
·
6 min read
BioMidwest

Humanetics Biomed expands its outsourced manufacturing capabilities to new markets

Humanetics Biomed is a Contract Development Manufacturing Organisation that combines the best biomedical technologies from Humanetics; with the technical engineering expertise for research and development of precision lasered components and subcomponents for medical devices.

May 19, 2023
·
3 min read
Drug Development

Epic Bio Presents Preclinical Data on EPI-321 for Facioscapulohumeral Muscular Dystrophy at ASGCT 26th Annual Meeting

Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, presented promising preclinical data supporting development of EPI-321 for the treatment of facioscapulohumeral muscular dystrophy.

May 19, 2023
·
2 min read
Pharm Country

KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Superior Therapeutic Efficacy of VET3-TGI at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

KaliVir Immunotherapeutics, Inc. announced the presentation of new data on its lead pre-clinical candidate VET3-TGI at the American Society of Gene & Cell Therapy 26th Annual Meeting.

May 19, 2023
·
3 min read
Genetown

Chroma Medicine Announces Data Demonstrating the Benefits of Epigenetic Editing for Multiplex Gene Regulation at ASGCT 2023

Chroma Medicine, Inc., a genomic medicine company pioneering single-dose epigenetic editing therapeutics, presented data demonstrating the advantages of epigenetic editing for multiplex gene regulation at the American Society of Gene & Cell Therapy 26th Annual Meeting in Los Angeles.

May 19, 2023
·
3 min read
Genetown

Be Biopharma Study Shows First Demonstration of Rapid Engraftment of B Cells without Preconditioning in Non-Human Primates with Intact Immune Systems

Be Biopharma, Inc., a company pioneering the discovery and development of Engineered B Cell Medicines, will present first-of-its-kind preclinical research from a collaboration study showing homing and engraftment of B cells in non-human primates with intact immune systems.

May 19, 2023
·
4 min read
Biotech Bay

Metagenomi Presents New Data on Novel Gene Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting

Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, presented new data for its gene editing programs during the 26th American Society of Gene + Cell Therapy Annual Meeting.

May 19, 2023
·
6 min read